(Q47811823)

English

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

scientific article published in March 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

childhood acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

9

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

Hartmut Döhner

8

object named as

Hartmut Döhner

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

Jorge Eduardo Cortes

2

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

Christoph Huber

7

object named as

Christoph Huber

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

Walter E Aulitzky

4

object named as

Walter Aulitzky

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

author name string

Florian Heidel

1

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

Frank G Rücker

3

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

Laurie Letvak

5

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

Thomas Kindler

6

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

Thomas Fischer

10

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

language of work or name

0 references

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

109

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

5

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

907-914

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

21 January 2018

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Myelodysplastic syndromes standardized response criteria: further definition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

FMS mutations in myelodysplastic, leukemic, and normal subjects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22471

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22471

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/17285599

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47811823&oldid=2172033494"